# BPC-157 Legal Status, FDA 503A Category, and Compounding Access | BPC-157 > BPC-157 legal status: FDA placed BPC-157 in 503A Category 2 (significant safety risks) effective with its September 29, 2023 update, and it is on the July 23-24, 2026 PCAC agenda as a substance under evaluation. General regulatory information, not advice. A status board of the FDA-citable facts: BPC-157 sits in 503A Category 2 today, and it is individually named on the July 2026 PCAC agenda as a substance under evaluation. What that does — and does not — mean for compounded access. ## The current FDA fact, stated present-tense BPC-157 legal status, read from the FDA record, is this: BPC-157 — the FDA list entries "BPC-157 (free base)" and "BPC-157 acetate" — is a research peptide that FDA placed in 503A "Category 2," the category for bulk substances that may present significant safety risks [16]. The placement took effect with FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A, and FDA's stated rationale included concerns about potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [16]. Two consequences follow directly from that category, and the console reads them as status flags. First, a Category 2 substance is not within FDA's enforcement-discretion policy for 503A compounding — FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance [17]. Second, BPC-157 is not an FDA-approved drug; whether a bulk substance may be used in compounding is a separate question from whether any finished drug has been approved, and no approved BPC-157 drug exists [17]. The framework behind those flags: under the Federal Food, Drug, and Cosmetic Act, Section 503A covers patient-specific compounding by state-licensed pharmacies and physicians, and Section 503B covers FDA-registered outsourcing facilities compounding larger batches [18]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet listed are evaluated through a public nomination process [18]. ## The forward read: under active evaluation, scheduled for July 2026 Here is the momentum, anchored to a fact rather than a forecast: access is under active FDA review and may expand in 2026, because BPC-157 is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026 [19]. The agenda lists BPC-157 as a bulk drug substance "being considered for inclusion on the 503A Bulks List," alongside KPV, TB-500, and MOTs-C [19]. What that is, precisely: a scheduled evaluation and discussion. The console states it as exactly that and no more. Being discussed by PCAC is a step in FDA's evaluation, not a final listing decision — inclusion on a final bulks list is decided by FDA rulemaking informed by the committee [18]. The July 2026 meeting is therefore a scheduled discussion of a substance under evaluation; it is not a listing decision, not a reclassification, and not a change in BPC-157's current status [19]. What this console will not do: it will not state any reclassification as already done, dated, or certain. Separately, FDA finalized a revised interim policy under which, from January 7, 2025, it no longer sorts newly nominated bulk substances into these numbered categories; substances already in Category 2 are not afforded enforcement discretion even if their nominations are updated [21]. Reports circulating in early 2026 of a broad move of Category 2 peptides back toward Category 1, and specific vendor claims that BPC-157 was "removed" from Category 2 in April 2026, could not be confirmed from an authoritative FDA source and are not treated as fact here. The FDA agenda still listing BPC-157 for July 2026 evaluation is consistent with the matter being ongoing rather than resolved [19]. The status this board displays is the last FDA-confirmable position: Category 2, under evaluation. ## How legally compounded peptide access works Compounded medication access in the U.S. follows one lawful pathway, and the console describes it in general terms only. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [20]. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription [20]. That prescription is then dispensed by a state-licensed 503A compounding pharmacy for an individual patient, or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility [20]. Telehealth sits at the front of that pathway as one channel for the prescriber-evaluation step — a route to a licensed-prescriber consultation and prescription, not a separate legal status [20]. It does not expand which substances may be compounded, and it does not remove the requirement for a legitimate clinical evaluation and a valid prescription [20]. The ingredient-eligibility caveat is the one that governs BPC-157 specifically. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A and 503B bulk-substance rules; ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [20]. Because BPC-157 is a Category 2 substance today, it is not eligible for routine 503A compounding while that category holds [16][17]. This page names no pharmacy, clinic, telehealth provider, or vendor, gives no dosing or administration instruction, and describes no way to obtain a restricted substance outside the lawful framework. It is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. ### Can you get BPC-157 from a compounding pharmacy? Under the current framework, a Category 2 bulk substance is not eligible for routine 503A compounding while that status stands, and BPC-157 sits in Category 2 today [16][20]. Legally compounded access generally requires a licensed-prescriber evaluation and a valid patient-specific prescription, with the preparation made by a 503A pharmacy or 503B outsourcing facility — but only if the ingredient is eligible under the bulk-substance rules [20]. This is general information, not advice, and names no provider. ### What is the FDA 503A status of BPC-157? FDA placed BPC-157 — the entries "BPC-157 (free base)" and "BPC-157 acetate" — in 503A Category 2, the category for bulk substances FDA identified as raising significant safety risks, effective with its September 29, 2023 update, citing immunogenicity and impurity-characterization concerns [16]. As a Category 2 substance it is not covered by FDA's enforcement-discretion policy [17]. BPC-157 is also on the July 23-24, 2026 PCAC agenda as a substance under evaluation for the 503A bulks list — a scheduled discussion, not a decision [19]. ## WADA status and the research-chemical reality Beyond the FDA framework, the [WADA prohibition status](/legal-status) is a separate flag relevant to athletes. BPC-157 is prohibited in sport at all times by the World Anti-Doping Agency under its S0 non-approved-substances category [22]. That prohibition is independent of the compounding question and applies regardless of route or context within sport. One more present-tense reality the console keeps visible: BPC-157 is not an approved drug anywhere and is widely distributed through non-regulated channels, which means product identity, purity, and dose are unverified outside formal studies [12]. That is a factual feature of the current landscape, stated for context — not guidance, and not a route around the framework above. ### Is BPC-157 legal? BPC-157 is not an FDA-approved drug, and FDA placed it in 503A "Category 2" (bulk substances that may present significant safety risks) effective with its September 29, 2023 update, meaning it is not within FDA's enforcement-discretion policy for 503A compounding [16][17]. It is also prohibited in sport at all times by WADA under the S0 category [22]. This is general regulatory information, not legal advice. --- A liquid-glass console reading of the peer-reviewed BPC-157 record — each datum refracted back to its source, the human-data gap left lit, and no clinic behind the panel.